<DOC>
	<DOCNO>NCT03004404</DOCNO>
	<brief_summary>The primary objective Single-rising dose ( SRD ) part ( trial part 1 ) investigate safety tolerability BI 730357 healthy subject follow oral administration single rise dos . The secondary objective exploration pharmacokinetics ( PK ) include dose proportionality , pharmacodynamics BI 730357 single dosing . The objective Bioavailability ( BA ) part ( trial part 2 ) explore relative bioavailability tablet fast versus oral solution fast influence food bioavailability tablet fast versus tablet fed .</brief_summary>
	<brief_title>To Assess Safety , Tolerability Pharmacokinetics BI 730357 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male accord Investigator 's assessment , base complete medical history include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age 18 45 year ( incl . ) Body Mass index ( BMI ) 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include Blood Pressure ( BP ) , Pulse Rate ( PR ) Electrocardiogram ( ECG ) ) deviate normal judge clinically relevant Investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 50 90 beat per minute ( bpm ) Any laboratory value outside reference range Investigator consider clinical relevance Any evidence concomitant disease judge clinically relevant Investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Use drug within 30 day prior administration trial medication might reasonably influence result trial ( incl . QT/QTc ( correct QT ) interval prolongation ) Participation another trial investigational drug administer within 60 day prior plan administration trial medication , current participation another trial involve administration investigational drug Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke specify trial day Alcohol abuse ( consumption 30 g per day male ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion Investigator , instance , consider able understand comply study requirement , condition would allow safe participation study In addition , follow trialspecific exclusion criterion apply : Male subject Women childbearing potential ( WOCBP ) partner unwilling use male contraception ( condom sexual abstinence ) first administration trial medication 30 day last administration trial medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>